 Andrew Kent
Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 6 | 2023 | 592 | 2.240 |
Why?
| | Hematologic Neoplasms | 2 | 2023 | 140 | 1.450 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 573 | 1.180 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 21 | 0.900 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 132 | 0.860 |
Why?
| | Inflammasomes | 1 | 2025 | 126 | 0.840 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 99 | 0.840 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 166 | 0.830 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2025 | 328 | 0.790 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 64 | 0.770 |
Why?
| | Hematopoietic Stem Cells | 1 | 2025 | 381 | 0.740 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 278 | 0.640 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1928 | 0.630 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2021 | 704 | 0.530 |
Why?
| | Genetic Variation | 1 | 2021 | 937 | 0.500 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 964 | 0.450 |
Why?
| | Signal Transduction | 2 | 2025 | 4925 | 0.370 |
Why?
| | Neoplasms | 3 | 2021 | 2470 | 0.360 |
Why?
| | Stem Cell Transplantation | 2 | 2023 | 166 | 0.350 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 295 | 0.300 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2023 | 215 | 0.270 |
Why?
| | T-Lymphocyte Subsets | 2 | 2021 | 412 | 0.250 |
Why?
| | Stromal Cells | 1 | 2025 | 107 | 0.230 |
Why?
| | ras Proteins | 1 | 2025 | 144 | 0.220 |
Why?
| | Lymphoma, B-Cell | 1 | 2025 | 105 | 0.210 |
Why?
| | Gamma Rays | 1 | 2023 | 54 | 0.210 |
Why?
| | Carcinogenesis | 1 | 2025 | 213 | 0.210 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 75 | 0.200 |
Why?
| | Azacitidine | 1 | 2023 | 139 | 0.200 |
Why?
| | Sulfonamides | 2 | 2023 | 496 | 0.200 |
Why?
| | Phagocytes | 1 | 2023 | 97 | 0.190 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 241 | 0.190 |
Why?
| | Cell Engineering | 1 | 2021 | 9 | 0.190 |
Why?
| | CD3 Complex | 1 | 2021 | 103 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2021 | 88 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 139 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2023 | 277 | 0.170 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 548 | 0.170 |
Why?
| | Recurrence | 1 | 2023 | 1007 | 0.170 |
Why?
| | Humans | 10 | 2025 | 129650 | 0.160 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 155 | 0.160 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 89 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 634 | 0.160 |
Why?
| | Benzimidazoles | 1 | 2020 | 162 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 333 | 0.160 |
Why?
| | Mice, Knockout | 1 | 2025 | 2871 | 0.140 |
Why?
| | Retrospective Studies | 3 | 2024 | 14518 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2025 | 2391 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5440 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 589 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1565 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 743 | 0.140 |
Why?
| | Immunotherapy | 1 | 2021 | 592 | 0.130 |
Why?
| | Protein Binding | 1 | 2021 | 2121 | 0.120 |
Why?
| | Animals | 5 | 2025 | 35361 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2014 | 84 | 0.110 |
Why?
| | Mice | 4 | 2025 | 16937 | 0.100 |
Why?
| | Neuronal Apoptosis-Inhibitory Protein | 1 | 2012 | 2 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2014 | 857 | 0.090 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 182 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 179 | 0.090 |
Why?
| | Calcium-Binding Proteins | 1 | 2012 | 210 | 0.090 |
Why?
| | Cancer Vaccines | 1 | 2012 | 164 | 0.090 |
Why?
| | Mutation | 1 | 2021 | 3717 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2024 | 10230 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 3973 | 0.080 |
Why?
| | Young Adult | 1 | 2024 | 12426 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2014 | 1902 | 0.070 |
Why?
| | Adolescent | 1 | 2024 | 20393 | 0.060 |
Why?
| | Child | 1 | 2024 | 20883 | 0.060 |
Why?
| | Middle Aged | 1 | 2024 | 31154 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 120 | 0.050 |
Why?
| | Adult | 1 | 2024 | 35576 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2014 | 1106 | 0.040 |
Why?
| | Male | 2 | 2024 | 63681 | 0.040 |
Why?
| | Female | 2 | 2024 | 68776 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 2014 | 128 | 0.030 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 67 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2014 | 218 | 0.030 |
Why?
| | Influenza A virus | 1 | 2014 | 100 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 331 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2014 | 161 | 0.030 |
Why?
| | Cell Separation | 1 | 2014 | 316 | 0.030 |
Why?
| | Flagellin | 1 | 2012 | 17 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1156 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2014 | 2119 | 0.020 |
Why?
| | Transcriptome | 1 | 2014 | 887 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1056 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3215 | 0.010 |
Why?
| | Aged | 1 | 2022 | 22103 | 0.010 |
Why?
|
|
Kent's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|